索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]高飞,杨明.机械循环支持治疗急性心肌梗死合并心源性休克[J].国际心血管病杂志,2023,06:379-382.
点击复制

机械循环支持治疗急性心肌梗死合并心源性休克(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年06期
页码:
379-382
栏目:
综述
出版日期:
2023-11-20

文章信息/Info

Title:
-
作者:
高飞; 杨明
110001 沈阳，中国医科大学研究生院（ 高飞）； 115003 营口市中心医院心内科（杨明）
Author(s):
-
关键词:
急性心肌梗死; 心源性休克; 机械循环支持; 机械相关不良事件
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.06.011
文献标识码:
-
摘要:
心源性休克是急性心肌梗死患者常见的死亡原因。目前应用于心源性休克的机 械循环支持包括主动脉内球囊反搏、左心室至主动脉泵、左心房至主动脉泵及体外膜肺氧 合等。该文介绍急性心肌梗死合并心源性休克应用机械循环支持的临床研究进展。
Abstract:
-

参考文献/References

[1] Tavazzi G, Rossello X, Grand J, et al. Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC-acute cardiovascular care association research section[J]. Eur Heart J Acute Cardiovasc Care, 2022, 11(9):706-711.
[2] Thiele H, Ohman EM, de Waha-Thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019[J]. Eur Heart J, 2019, 40(32):2671-2683.
[3] Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based care for cardiogenic shock[J]. J Am Coll Cardiol, 2019, 73(13):1659-1669.
[4] Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes[J]. Circulation, 2008, 117(5):686-697.
[5] Tarvasm?ki T, Lassus J, Varpula M, et al. Current real-life use of vasopressors and inotropes in cardiogenic shock— adrenaline use is associated with excess organ injury and mortality[J]. Crit Care, 2016, 20(1):208.
[6] Wang JI, Lu DY, Mhs, et al. Outcomes of hospitalizations for cardiogenic shock at left ventricular assist device versus nonleft ventricular assist device centers[J]. J Am Heart Assoc, 2020, 9(23):e017326.
[7] Basir MB, Kapur NK, Patel K, et al. Investigators.improved outcomes associated with the use of shock protocols:updates from the National cardiogenic shock initiative[J]. Catheter Cardiovasc Interv, 2019, 93(7):1173-1183.
[8] Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock[J]. N Engl J Med, 2012, 367(14):1287-1296.
[9] Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK Ⅱ): final 12 month results of a randomised, open-label trial[J]. Lancet, 2013, 382(9905):1638-1645.
[10] Thiele H, Zeymer U, Thelemann N, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABPSHOCK Ⅱ trial[J]. Circulation, 2019, 139(3):395-403.
[11] Werdan K, Buerke M, Geppert A, et al. Infarction-related cardiogenic shock—diagnosis, monitoring and therapy–a German-Austrian S3 guideline[J]. Dtsch Arztebl Int, 2021, 118(6):88-95.
[12] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119-177.
[13] Akodad M, Delmas C, Bonello L, et al. Intra-aortic balloon pump: is the technique really outdated?[J]. ESC heart failure, 2020, 7(3):1025-1030.
[14] O'Neill BP, Grines C, Moses JW, et al. Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention[J]. Catheter Cardiovasc Interv, 2021, 98(4):E501-E512.
[15] Batsides G, Massaro J, Cheung A, et al. Outcomes of impella 5.0 in cardiogenic shock: a systematic review and metaanalysis[ J]. Innovations (Phila), 2018, 13(4):254-260.
[16] Alushi B, Douedari A, Froehlig G, et al. Impella versus IABP in acute myocardial infarction complicated by cardiogenic shock[J]. Open heart, 2019, 6(1):e000987.
[17] Amin AP, Spertus JA, Curtis JP, et al. The evolving landscape of impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support[J]. Circulation, 2020, 141(4):273-284.
[18] Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/ HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention[J]. J Am Coll Cardiol, 2015, 65(19):e7-e26.
[19] Berg DD, Sukul D, O'Brien M, et al. Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock[J]. Eur Heart J Acute Cardiovasc Care, 2016, 5(2):108-116.
[20] Ostadal P, Mlcek M, Holy F, et al. Direct comparison of percutaneous circulatory support systems in specific hemodynamic conditions in a porcine model[J]. Circ Arrhythm Electrophysiol, 2012, 5(6):1202-1206.
[21] Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock—a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2020, 22(8):1315-1341.
[22] Nascimbene A, Loyalka P, Gregoric ID, et al. Percutaneous coronary intervention with the TandemHeart? percutaneous left ventricular assist device support: six years of experience and outcomes[J]. Catheter Cardiovasc Interv, 2016, 87(6):1101-1110.
[23] Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock[J]. J Am Coll Cardiol, 2011, 57(6):688-696.
[24] Acharya D, Torabi M, Borgstrom M, et al. Extracorporeal membrane oxygenation in myocardial infarction complicated by cardiogenic shock: analysis of the ELSO registry[J]. J Am Coll Cardiol, 2020, 76(8):1001-1002.
[25] Nishi TKH, Ishii M, Tsujita K, et al. Outcomes of venoarterial extracorporeal membrane oxygenation plus intra-aortic balloon pumping for treatment of acute myocardial infarction complicated by cardiogenic shock[J]. J Am Heart Assoc, 2022, 11(7):e023713.
[26] Estep JD, Starling RC, Horstmanshof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study[J]. J Am Coll Cardiol, 2015, 66(16):1747-1761.
[27] Dudek D, Ebner A, Sobczyński R, et al. Efficacy and safety of the HeartMate percutaneous heart pump during high-risk percutaneous coronary intervention (from the SHIELD I trial) [J]. Am J Cardiol, 2018, 121(12):1524-1529.
[28] Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure[J]. N Engl J Med, 2017, 376(5):440-450.

备注/Memo

备注/Memo:
通信作者：杨明， E-mail：ff201602468@163.com
更新日期/Last Update: 2023-11-20